WeTrials

A Phase 1/1B, Open-Label, Dose Escalation and Expansion Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced Solid Tumors Expressing HER2

What is this study?

This study is testing a new cancer medicine called SBT6050, both by itself and combined with other immune-boosting drugs, for people with advanced tumors that have high levels of the HER2 protein. Researchers want to find the safest and most effective dose to help the body's immune system fight the cancer.

Who can participate?

You might be able to join if you have advanced cancer with HER2 proteins, have already tried standard treatments, and are well enough to carry out daily activities. People with untreated brain metastases, certain immune system conditions, or active infections like HIV or hepatitis cannot participate.

What will happen?

Participants will receive the investigational study drug SBT6050, either alone or with an immunotherapy drug, while being closely monitored by the medical team. You will need to provide a recent tumor sample and undergo regular scans and check-ups to see how your body responds.

Where and when?

The study is taking place at medical centers in Boston, Massachusetts; Durham, North Carolina; and Pittsburgh, Pennsylvania. The current status of the study is listed as unknown, so we recommend reaching out directly to the study locations to check if they are actively enrolling.

Key Points
  • 1Testing a new targeted cancer drug called SBT6050 for tumors with the HER2 protein.
  • 2Combines the new drug with existing immunotherapy treatments to help fight cancer.
  • 3Requires previous standard treatments and regular check-ups at participating U.S. locations.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
HER2 Positive Solid Tumors

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.